Patients with advanced non-small-cell lung cancer presenting with greater CD8+ T cell infiltration exhibit a superior treatment response to pembrolizumab, an anti-PD-1 drug (Garon et al., 2019). Here, CD8A is linked to non-small cell lung carcinoma.